Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02419560
Title Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Craig Portell, MD

mantle cell lymphoma


Ibrutinib + Venetoclax

Age Groups: adult
Covered Countries USA

No variant requirements are available.